69 related articles for article (PubMed ID: 18785538)
1. [Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line].
Qin YY; Li JY; Li SG; Yue JN; Quan ZW
Zhonghua Wai Ke Za Zhi; 2008 Mar; 46(5):381-3. PubMed ID: 18785538
[TBL] [Abstract][Full Text] [Related]
2. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation.
Quan ZW; Yang Y; Li JY; Gong W; Qin YY; Li SG
Biomed Pharmacother; 2010 Sep; 64(7):451-7. PubMed ID: 20359855
[TBL] [Abstract][Full Text] [Related]
3. [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration].
Gong W; Qin YY; Li SG; Quan ZW; Li JY; Zhuang PY; Wan ZW
Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2718-22. PubMed ID: 21162905
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of ICBP90 contributes to doxorubicin resistance.
Wang J; Song Y; Xu S; Zhang Q; Li Y; Tang D; Jin S
Eur J Pharmacol; 2011 Apr; 656(1-3):33-8. PubMed ID: 21296067
[TBL] [Abstract][Full Text] [Related]
7. The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma.
Li JY; Quan ZW; Zhang Q; Liu JW
BMC Cancer; 2007 Jul; 7():125. PubMed ID: 17617924
[TBL] [Abstract][Full Text] [Related]
8. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
10. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
World J Gastroenterol; 2005 Apr; 11(16):2431-7. PubMed ID: 15832413
[TBL] [Abstract][Full Text] [Related]
11. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
[TBL] [Abstract][Full Text] [Related]
12. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
13. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
14. Influence of norcantharidin on proliferation, proliferation-related gene proteins proliferating cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):603-7. PubMed ID: 15567755
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
16. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
20. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
